FDA Grants Orphan Drug Designation to Novel Mesothelioma Treatment
The U.S. Food and Drug Administration has granted orphan drug designation to ONCOFID-P for the treatment of malignant pleural mesothelioma, a step toward another potential therapy option for patients. ONCOFID-P is an innovative drug conjugate already in advanced clinical development for the treatment of invasive bladder cancer. The mesothelioma designation is based on preclinical data showing high antitumor activity in laboratory and mice models. Fidia Farmaceutici, a multinational research company based in Italy, announced the latest FDA designation, which is designed to encourage the development of novel drugs, par...
Source: Asbestos and Mesothelioma News - July 28, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Advanced bladder cancers respond to immunotherapy regardless of gene mutation status
(UNC Lineberger Comprehensive Cancer Center) UNC Lineberger researchers and colleagues report a study has demonstrated that patients with advanced bladder cancers whose tumors have a mutated FGFR3 gene respond to immunotherapy in a manner that is similar to patients without that mutation. This discovery runs counter to previous research that suggested FGFR3-mutated bladder cancers should not be treated with immunotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 22, 2021 Category: Cancer & Oncology Source Type: news

New Drug Combination Shows Promise for Peritoneal Mesothelioma
Researchers at MD Anderson Cancer Center in Houston have uncovered a new, promising treatment option for patients with peritoneal mesothelioma, potentially filling a gaping void that exists today. The immunotherapy drug combination of Tecentriq and Avastin, known generically as atezolizumab and bevacizumab, respectively, showed unusual efficacy in a recent study of 20 patients with this rare cancer. Although some patients have previously found significant success and extended survival with the cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combination, or HIPEC, those with unresectable disease ha...
Source: Asbestos and Mesothelioma News - July 21, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Undone Proteins Take Out Bladder Cancer
An unfolded protein found in human milk shows promise in early clinical trials to treat bladder cancer. (Source: The Scientist)
Source: The Scientist - July 20, 2021 Category: Science Tags: Sponsored Article Source Type: news

First in Human Procedure with Vessi Medical's Cryotherapy System for Bladder Cancer
MISGAV, Israel, July 14, 2021 -- (Healthcare Sales & Marketing Network) -- Vessi Medical ("Vessi"), announced that it successfully completed a first-in-human case with its minimally invasive cryoablation solution for superficial bladder cancer ... Devices, Urology, Oncology Vessi Medical, cryoablation, bladder cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 14, 2021 Category: Pharmaceuticals Source Type: news

Cancer symptoms: Seven common warning signs of a growing tumour in the prostate
CANCEROUS cells that are pushing up against the urethra - the tube that carries urine from the bladder out through the tip of the penis - will cause bodily sensations. (Source: Daily Express - Health)
Source: Daily Express - Health - July 11, 2021 Category: Consumer Health News Source Type: news

Oncotarget: Urine RNA reveal tumor markers for human bladder cancer
(Impact Journals LLC) This Oncotarget work strongly suggests exploiting urine RNAs as diagnostic markers of bladder cancer and it suggests specific novel markers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 9, 2021 Category: Cancer & Oncology Source Type: news

Carbogen and Nicotinamide With Radiation Feasible for Bladder Cancer
THURSDAY, July 8, 2021 -- The use of concurrent carbogen and nicotinamide (CON) with radiation therapy is feasible for patients with muscle invasive bladder cancer (MIBC) in the Australian setting, according to a study published online June 30 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 8, 2021 Category: Pharmaceuticals Source Type: news

Nicotine by-product can predict recurrence of cancer
(European Association of Urology) A by-product of nicotine, found in the urine of smokers, could be used to identify when bladder cancer has returned, new research has found. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 8, 2021 Category: Cancer & Oncology Source Type: news

Aging-related conditions increase treatment burden in older cancer patients
(Geisinger Health System) Having multiple chronic health conditions and living in a rural area were the top two factors affecting increased healthcare system contact among older patients with bladder cancer, a research team has found. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2021 Category: Cancer & Oncology Source Type: news

New model aims to promote better-adapted bladder cancer treatment in the future
(Uppsala University) Uppsala University scientists have designed a new mouse model that facilitates study of factors contributing to the progression of human bladder cancer and of immune-system activation when the tumour is growing. Using this model, they have been able to study how proteins change before, while and after a tumour develops in the bladder wall. The study has now been published in the scientific journal PLOS ONE. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2021 Category: Cancer & Oncology Source Type: news

New approach todrug design yields highly promising bladder cancer drug candidate
(Trinity College Dublin) A new approach to molecular drug design has yielded a highly promising bladder cancer drug, which induced rapid shedding of tumour cells and resulted in a significant reduction in tumour size when used in clinical trials. These potent effects were seen in patients with non-muscle invasive bladder cancer (NMIBC) and the treatment was shown to be safe, as no drug-related side effects were observed. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 28, 2021 Category: Cancer & Oncology Source Type: news

Study suggests blood test could guide precision treatment in bladder cancer
(Queen Mary University of London) A blood test that can detect tiny amounts of circulating cancer DNA may be able to identify risk of cancer recurrence and guide precision treatment in bladder cancer following surgery, according to a clinical study led by Professor Tom Powles from Queen Mary University of London and Barts Health NHS Trust. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 21, 2021 Category: Cancer & Oncology Source Type: news

Cancer symptoms: Toilet troubles that are indicative of a growing tumour in the bladder
CANCER cells can amass into a tumour along the bladder lining, and in some cases, it can spread into the muscle. When cancer is present in that area of the body, toilet troubles start to emerge. Do you know what to look out for? (Source: Daily Express - Health)
Source: Daily Express - Health - June 12, 2021 Category: Consumer Health News Source Type: news

How to Avoid Cystectomy in Muscle-Invasive Bladder Cancer How to Avoid Cystectomy in Muscle-Invasive Bladder Cancer
Nearly half the patients with muscle-invasive bladder cancer had clinical complete responses, showing that bladder-intact recurrence-free survival is possible.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 8, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

ASCO: Bladder Sparing Studied in Muscle - Invasive Bladder Cancer
Transurethral resection then gemcitabine, cisplatin, plus nivolumab with intact bladder in selected patients studied in phase 2 trial (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 7, 2021 Category: Cancer & Oncology Tags: Oncology, Pathology, Pharmacy, Urology, Conference News, Source Type: news

Can You Keep Your Bladder After Bladder Cancer Strikes?
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 7, 2021 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Surgery, News, Source Type: news

ASCO: Bladder Sparing Studied in Muscle-Invasive Bladder Cancer
MONDAY, June 7, 2021 -- For patients with muscle-invasive bladder cancer, transurethral resection and combination treatment with gemcitabine, cisplatin, plus nivolumab with bladder sparing is feasible in selected patients, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 7, 2021 Category: Pharmaceuticals Source Type: news

Can You Keep Your Bladder After Bladder Cancer Strikes?
MONDAY, June 7, 2021 -- After being diagnosed with bladder cancer, some patients face an almost impossible decision -- have their bladder removed or take a risk knowing that the cancer may be more likely to spread if the bladder is left intact. But... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 7, 2021 Category: General Medicine Source Type: news

Can You Keep Your Bladder After Bladder Cancer Strikes?
Title: Can You Keep Your Bladder After Bladder Cancer Strikes?Category: Health NewsCreated: 6/7/2021 12:00:00 AMLast Editorial Review: 6/7/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - June 7, 2021 Category: Cancer & Oncology Source Type: news

Study shows novel test can detect new and recurrent bladder cancer
Detection of bladder cancer is often difficult and expensive, but this non-invasive urine screening test could make a significant positive impact. (Source: Yale Science and Health News)
Source: Yale Science and Health News - June 4, 2021 Category: Universities & Medical Training Source Type: news

Immunotherapy after bladder cancer surgery may reduce recurrence, study shows
(Memorial Sloan Kettering Cancer Center) ew research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD, and colleagues found that patients who received nivolumab (Opdivo ® ) after bladder cancer surgery reduced their overall risk for high-grade bladder cancer recurrence. This research was published in theNew England Journal of Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 3, 2021 Category: Cancer & Oncology Source Type: news

Immunotherapy after surgery reduces deadly relapse risk in advanced bladder cancer
(The Mount Sinai Hospital / Mount Sinai School of Medicine) A phase 3 clinical trial co-led by Mount Sinai researchers is the first to show that immunotherapy after surgery to remove bladder cancer can reduce the risk of relapse for patients who are at high risk of their cancer returning in a deadly metastatic form, according to results published in The New England Journal of Medicine. The immunotherapy nivolumab was used as an adjuvant therapy, which is given after surgery in the hopes of maximizing its effectiveness. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 2, 2021 Category: Cancer & Oncology Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Finding new cost-effective treatment options for BCG-unresponsive bladder cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2021 Category: Drugs & Pharmacology Source Type: news

Oncotarget: Progression in high-risk non-muscle invasive bladder cancer
(Impact Journals LLC) This Oncotarget study examined the importance of the De Ritis ratio as a prognostic marker in high-risk NMIBC (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2021 Category: Cancer & Oncology Source Type: news

Cancer symptoms: Toilet troubles may be indicative of a growing tumour – signs
CANCER can influence how you use the toilet. A growing tumour - depending on where it is - can cause difficulties when it comes to emptying the bowels and bladder. Here are the warning signs to take note of. (Source: Daily Express - Health)
Source: Daily Express - Health - May 30, 2021 Category: Consumer Health News Source Type: news

Oncotarget: Urine protein biomarkers of bladder cancer
(Impact Journals LLC) These Oncotarget findings suggest that urine IL-1α, IL-1ra and IL-8 are useful indicators of bladder cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 24, 2021 Category: Cancer & Oncology Source Type: news

Mayo Clinic Q & amp;A podcast: Bladder cancer patients require ongoing surveillance
Bladder cancer is a common type of cancer that begins in the cells of the bladder, a hollow muscular organ in the lower abdomen that stores urine. Bladder cancer signs and symptoms can include blood in the urine, frequent or painful urination, and back pain. "The vast majority of bladder cancer patients are diagnosed with cancer that's not [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 17, 2021 Category: Databases & Libraries Source Type: news

Consumer Health: Bladder cancer awareness
May is Bladder Cancer Awareness Month, which makes this a good time to learn more about bladder cancer. Bladder cancer is one of the most common cancers. Nearly 84,000 new cases will be diagnosed in the U.S. in 2021, according to the American Cancer Society. Bladder cancer occurs in men more frequently than in women, [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 13, 2021 Category: Databases & Libraries Source Type: news

How Long Will You Live if You Have Bladder Cancer?
Title: How Long Will You Live if You Have Bladder Cancer?Category: Diseases and ConditionsCreated: 5/6/2021 12:00:00 AMLast Editorial Review: 5/6/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 6, 2021 Category: Cancer & Oncology Source Type: news

What Are the Different Stages of Bladder Cancer?
Title: What Are the Different Stages of Bladder Cancer?Category: Diseases and ConditionsCreated: 4/30/2021 12:00:00 AMLast Editorial Review: 4/30/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 30, 2021 Category: Cancer & Oncology Source Type: news

To Stay: Two More Cancer Indications With'Dangling Approvals'To Stay: Two More Cancer Indications With'Dangling Approvals '
On the second day of a historic meeting, FDA advisers voted to keep the accelerated approvals for two immunotherapies for use in bladder cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 29, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for previously untreated metastatic bladder cancer
Basel, 28 April 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 1 in favour of maintaining accelerated approval of Tecentriq® (atezolizumab) for the treatment of adults with locally advanced or metastatic urothel ial carcinoma (mUC, bladder cancer) who are not eligible for cisplatin-containing chemotherapy and whose tumours express high levels of PD-L1 (PD-L1–stained tumour-infiltrating immune cells covering ≥5 percent of the tumour area) as determined by an FDA-approved test or are not eligible for ...
Source: Roche Investor Update - April 28, 2021 Category: Pharmaceuticals Source Type: news

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for previously untreated metastatic bladder cancer
Basel, 28 April 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 1 in favour of maintaining accelerated approval of Tecentriq® (atezolizumab) for the treatment of adults with locally advanced or metastatic urothel ial carcinoma (mUC, bladder cancer) who are not eligible for cisplatin-containing chemotherapy and whose tumours express high levels of PD-L1 (PD-L1–stained tumour-infiltrating immune cells covering ≥5 percent of the tumour area) as determined by an FDA-approved test or are not eligible for ...
Source: Roche Media News - April 28, 2021 Category: Pharmaceuticals Source Type: news

Male bladder cancer vulnerability could lead to a new treatment approach
(University of California - Davis Health) UC Davis Comprehensive Cancer Center researchers found that targeting androgen receptors - a type of protein that is crucial for the function of testosterone - may destroy cancer cells. Focusing on this protein variant common in malignant bladder tumor cells may serve as a new avenue for treating bladder cancer in men. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 28, 2021 Category: International Medicine & Public Health Source Type: news

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Media News - April 27, 2021 Category: Pharmaceuticals Source Type: news

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Investor Update - April 27, 2021 Category: Pharmaceuticals Source Type: news

What Are the 5 Warning Signs of Bladder Cancer?
Title: What Are the 5 Warning Signs of Bladder Cancer?Category: Diseases and ConditionsCreated: 4/22/2021 12:00:00 AMLast Editorial Review: 4/22/2021 12:00:00 AM (Source: MedicineNet Hearing General)
Source: MedicineNet Hearing General - April 22, 2021 Category: Audiology Source Type: news

Therapeutic Cancer Vaccine Shows Promise Against Multiple Tumor Types
TUESDAY, April 13, 2021 -- Marc Baum went through all the usual steps to treat his bladder cancer -- a couple of surgeries, radiation therapy and chemotherapy, all in a three-month period. But doctors hope that an extra step -- an experimental... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 13, 2021 Category: General Medicine Source Type: news

Urinary Incontinence Surgery Won't Raise a Woman's Cancer Risk
NDAY, April 12, 2021 -- Women face no increased risk of pelvic cancer -- tumors of the bladder, cervix and ovaries -- if they have surgery to treat stress urinary incontinence (SUI), a new study finds. Concerns about possible complications and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 12, 2021 Category: General Medicine Source Type: news

Personalized cancer vaccine is safe, shows potential benefit against cancer
(The Mount Sinai Hospital / Mount Sinai School of Medicine) A personalized cancer vaccine developed with the help of a Mount Sinai computational platform raised no safety concerns and showed potential benefit in patients with different cancers, including lung and bladder, that have a high risk of recurrence, according to results from an investigator-initiated phase I clinical trial presented during the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, held April 10-15. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 10, 2021 Category: Cancer & Oncology Source Type: news

Genes and immune cells predict immunotherapy success in bladder cancer
(The Mount Sinai Hospital / Mount Sinai School of Medicine) Sets of genes associated with resistance to immunotherapy in patients with metastatic urothelial cancer of the bladder have been identified and validated by researchers at Mount Sinai. In a study published in Clinical Cancer Research, the team uncovered gene signatures representing adaptive immunity and pro-tumorigenic inflammation that were responsible for sensitivity or resistance to immune checkpoint inhibitors, drugs that help the body's immune system recognize and attack cancerous cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 9, 2021 Category: Cancer & Oncology Source Type: news

Resistance to Immunotherapy in Patients with Urothelial Bladder Cancer...
Sets of genes associated with resistance to immunotherapy in patients with metastatic urothelial cancer of the bladder have been identified and validated by researchers at Mount Sinai. In a study...(PRWeb April 09, 2021)Read the full story at https://www.prweb.com/releases/resistance_to_immunotherapy_in_patients_with_urothelial_bladder_cancer_is_traced_to_specific_sets_of_immune_cells/prweb17850269.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 9, 2021 Category: Pharmaceuticals Source Type: news

Artist Tracey Emin says her cancer is 'gone'
The 57-year-old was diagnosed with a "really rapid, really aggressive" bladder cancer last year. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - April 8, 2021 Category: Consumer Health News Source Type: news

Testing a new way to tackle cancer
(Michigan State University) A potential new weapon against cancer is entering the first phase of clinical trials. Michigan State University's Kurt Zinn, a professor of biomedical engineering, radiology and small animal clinical sciences, is leading the effort to validate an innovative radiotherapy as part of a safe, more effective and potentially less costly treatment for bladder cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 6, 2021 Category: International Medicine & Public Health Source Type: news

Phase III Trial of Durvalumab for Mesothelioma Underway
The U.S. Food and Drug Administration will be closely watching the latest, international phase III clinical trial for unresectable pleural mesothelioma involving the immunotherapy drug durvalumab. FDA approval may be coming soon. “It looks very promising,” Dr. Arkadiusz Dudek, of Regions Hospital Cancer Care Center in St. Paul, Minnesota, told The Mesothelioma Center at Asbestos.com. “The hope is to have the regimen approved by the FDA as front-line therapy. There is a real need today for more options with mesothelioma.” The goal of the randomized trial – officially known as DREAM3R &...
Source: Asbestos and Mesothelioma News - April 1, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

New study looks at long-term outcomes and costs of NMIBC
(University of Texas Medical Branch at Galveston) A new study published in JAMA Network Open details the results of treatment outcomes and the costs of medical care for patients with advanced bladder cancer using VA data over 15 years. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 31, 2021 Category: Cancer & Oncology Source Type: news

Decades of radiation-based scientific theory disproven by Ben-Gurion University US-based study
(American Associates, Ben-Gurion University of the Negev) According to the study, lower levels of several types of cancers were found when the radiation levels were on the higher end of the spectrum rather than on the lower end. Among both men and women, there was a significant decrease in lung, pancreatic, colon and rectal cancers. Among men, there were additional decreases in brain and bladder cancers. There was no decrease in cervix, breast or prostate cancers or leukemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 24, 2021 Category: International Medicine & Public Health Source Type: news

New breed of drug that reduces deaths from bladder cancer
The medicines, which are known as antibody-drug conjugates (ADCs), carry out chemotherapy-like attacks on cancer cells but don't cause side effects such as hair loss, fatigue and nausea. (Source: the Mail online | Health)
Source: the Mail online | Health - March 20, 2021 Category: Consumer Health News Source Type: news